Peptide Hormone Or Derivative Utilizing Patents (Class 514/5.3)
-
Publication number: 20120071402Abstract: Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Applicant: Novo Nordisk A/SInventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
-
Publication number: 20120071403Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.Type: ApplicationFiled: May 26, 2010Publication date: March 22, 2012Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Paul Strumph, Stephanie Moran, James List
-
Publication number: 20120071401Abstract: Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.Type: ApplicationFiled: April 9, 2010Publication date: March 22, 2012Applicant: Amylin Pharamaceuticals, Inc.Inventors: Jonathan David Roth, James L. Trevaskis, David G. Parkes
-
Publication number: 20120058939Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: July 1, 2010Publication date: March 8, 2012Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. GUZZO, Matthew David SURMAN, Alan John HENDERSON, Mark HADDEN, Emily Elizabeth FREEMAN
-
Publication number: 20120052130Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: April 12, 2010Publication date: March 1, 2012Inventors: Etzer Darout, Michael Paul DeNinno, Kentaro Futatsugi, Cristiano Ruch Werneck Guimaraes, Bruce Allen Lefker, Vincent Mascitti, Kim Francis McClure, Michael John Munchhof, Ralph Pelton Robinson, JR.
-
Publication number: 20120053118Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: ApplicationFiled: March 17, 2010Publication date: March 1, 2012Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Christine M. Mack, Jonathan David Roth
-
Publication number: 20120046222Abstract: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a ?-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.Type: ApplicationFiled: March 26, 2010Publication date: February 23, 2012Applicant: Amylin Pharmaceuticals, Inc.Inventors: Josue Alfaro-Lopez, Abhinandini Sharma, Soumitra S. Ghosh
-
Publication number: 20120021976Abstract: The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.Type: ApplicationFiled: April 1, 2010Publication date: January 26, 2012Inventors: Craig D. Boyle, Claire M. Lankin, Unmesh G. Shah, William J. Greenlee, Samuel Chackalamannil
-
Patent number: 8088730Abstract: The present invention concerns thirteen novel variants of alternative splicing of the obesity and/or diabetes related genes.Type: GrantFiled: October 13, 2006Date of Patent: January 3, 2012Inventor: Liat Mintz
-
Patent number: 8076281Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.Type: GrantFiled: September 10, 2008Date of Patent: December 13, 2011Assignee: IPSEN Pharma, S.A.S.Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
-
Publication number: 20110301080Abstract: The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.Type: ApplicationFiled: December 10, 2009Publication date: December 8, 2011Inventors: Mark A. Bush, Murray W. Stewart, Yonghong Yang
-
Publication number: 20110293587Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: December 1, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Publication number: 20110293516Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.Type: ApplicationFiled: April 11, 2011Publication date: December 1, 2011Inventors: RENATA PASQUALINI, WADIH ARAP, MIKHAIL G. KOLONIN
-
Publication number: 20110293586Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: December 1, 2011Applicant: ZEALAND PHARMA A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengern Daugaard
-
Patent number: 8067554Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.Type: GrantFiled: May 29, 2007Date of Patent: November 29, 2011Assignee: Novo Nordisk A/SInventor: Arne Staby
-
Publication number: 20110288011Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic. The compounds of the invention can be used to treat any disease for which the peptide therapeutic is useful.Type: ApplicationFiled: December 7, 2009Publication date: November 24, 2011Inventors: Jean-Paul Castaigne, Michel Demeule, Catherine Gagnon, Betty Lawrence
-
Publication number: 20110286981Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: November 24, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Publication number: 20110275559Abstract: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.Type: ApplicationFiled: May 18, 2009Publication date: November 10, 2011Applicant: Novo Nordisk A/SInventors: Søren Østergaard, Sanne Møller Knudsen, Jane Spetzler, Rasmus Jørgensen, Jacob Kofoed
-
Publication number: 20110263491Abstract: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.Type: ApplicationFiled: December 9, 2010Publication date: October 27, 2011Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Christian WEYER, Kevin D. Laugero, Christine M. Mack, David G. Parkes
-
Publication number: 20110257092Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: ApplicationFiled: June 16, 2009Publication date: October 20, 2011Inventors: Richard D. Dimarchi, David l. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day, James Patterson, Brian Ward
-
Publication number: 20110245162Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Applicant: Amylin Pharmaceuticals, Inc.Inventors: Mark FINEMAN, Leigh MacConell, Kristin Taylor
-
Publication number: 20110245161Abstract: The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or CHD and/or weight management and/or diabetes and/or hyperglycemia.Type: ApplicationFiled: March 27, 2007Publication date: October 6, 2011Inventor: Liat Mintz
-
Publication number: 20110237503Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.Type: ApplicationFiled: March 23, 2011Publication date: September 29, 2011Applicant: ELI LILLY AND COMPANYInventors: Jorge ALSINA-FERNANDEZ, Krister Bengt BOKVIST, Lili GUO, John Philip MAYER
-
Patent number: 8026210Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.Type: GrantFiled: January 14, 2009Date of Patent: September 27, 2011Assignee: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. Young, Bronislava Gedulin
-
Patent number: 8022035Abstract: Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, [Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36, [Glu10,Nle17,Nle30]PP2-36, their PP1-36 equivalents, and analogues and derivatives thereof as described in the specification, are selective agonists of the Y4 receptor relative to the Y1 and Y2 receptors, and are useful in the treatment, for example, of obesity and overweight, and conditions in which these are considered contributory factors, and in the treatment of diarrhoea and intestinal hypersecretion.Type: GrantFiled: September 21, 2005Date of Patent: September 20, 2011Assignee: 7TM Pharma A/SInventors: Thue Schwartz, Paul Brian Little, Lars-Ole Gerlach, Christian Elling
-
Publication number: 20110207661Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.Type: ApplicationFiled: November 1, 2010Publication date: August 25, 2011Applicant: Theracos, Inc.Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
-
Publication number: 20110183899Abstract: The invention relates to methods and compositions for the treatment of obesity. The methods and compositions relate to the use of an agent that reduces or prevents endoplasmic reticulum stress in conjunction with leptin.Type: ApplicationFiled: May 12, 2009Publication date: July 28, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Umut Ozcan, Lale Ozcan
-
Patent number: 7985835Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: November 13, 2006Date of Patent: July 26, 2011Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Harald Jüppner
-
Publication number: 20110178006Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.Type: ApplicationFiled: January 12, 2011Publication date: July 21, 2011Applicant: Emisphere Technologies, Inc.Inventors: Mohommed Amin KHAN, Bryan Edward Jones, John McNeil McGill
-
Patent number: 7981860Abstract: The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual.Type: GrantFiled: March 9, 2007Date of Patent: July 19, 2011Inventor: Liat Mintz
-
Publication number: 20110166062Abstract: Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.Type: ApplicationFiled: June 16, 2009Publication date: July 7, 2011Applicant: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, Ma Tao
-
Publication number: 20110152182Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.Type: ApplicationFiled: December 15, 2010Publication date: June 23, 2011Applicant: ELI LILLY AND COMPANYInventors: Jorge Alsina-Fernandez, Wayne David Kohn
-
Publication number: 20110152183Abstract: Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety is attached to the hybrid peptide, optionally via a linker.Type: ApplicationFiled: June 25, 2009Publication date: June 23, 2011Applicant: Novo Nordisk A/SInventors: Lauge Schäffer, Thomas Kruse
-
Publication number: 20110144008Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: December 1, 2010Publication date: June 16, 2011Inventors: Bjarne Due LARSEN, Jens Damsgaard Mikkelsen, Søren Neve
-
Publication number: 20110136733Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.Type: ApplicationFiled: August 7, 2009Publication date: June 9, 2011Inventor: Zheng Xin Dong
-
Publication number: 20110130329Abstract: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.Type: ApplicationFiled: September 22, 2006Publication date: June 2, 2011Inventors: Peter Geigle, Christine Wallrapp, Eric Thoenes
-
Publication number: 20110117049Abstract: Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.Type: ApplicationFiled: July 14, 2009Publication date: May 19, 2011Applicants: Joslin Diabetes Center, Inc., Children's Hospital BostonInventors: C. Ronald Kahn, Yu-Hua Tseng, Atul Butte
-
Patent number: 7939494Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.Type: GrantFiled: April 9, 2009Date of Patent: May 10, 2011Assignee: Emisphere Technologies, Inc.Inventors: Mohammed Amin Khan, Bryan Edward Jones, John McNeill McGill
-
Publication number: 20110092417Abstract: The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.Type: ApplicationFiled: July 23, 2008Publication date: April 21, 2011Applicant: ASTERION LIMITEDInventors: Peter Artymiuk, Richard Ross, Jon Sayers
-
Patent number: 7928060Abstract: The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent conditions such as metabolic and cardiovascular disorders, e.g., obesity, diabetes, metabolic syndrome, myocardial ischemia, and increased cardiovascular risk.Type: GrantFiled: October 11, 2005Date of Patent: April 19, 2011Assignee: Amylin Pharmaceuticals, Inc.Inventors: Mary Erickson, Ved Srivastava, Sarah McQuaid, Andrew Young, Richard Pittner, Soumitra Ghosh
-
Publication number: 20110081426Abstract: The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 9, 2010Publication date: April 7, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20110034374Abstract: Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.Type: ApplicationFiled: January 29, 2010Publication date: February 10, 2011Applicant: Imperial Innovations LimitedInventors: Stephen Robert Bloom, Mohammad Ali Ghatei, Caroline Jane Small, Catherine Louise Dakin
-
Publication number: 20110034373Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.Type: ApplicationFiled: July 30, 2008Publication date: February 10, 2011Applicant: ELI LILLY AND COMPANYInventors: Tamer Coskun, Wolfgang Glaesner
-
Publication number: 20110034375Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.Type: ApplicationFiled: October 19, 2010Publication date: February 10, 2011Inventors: William N. Washburn, Saleem Ahmad, Andres S. Hernandez
-
Publication number: 20110020460Abstract: Compounds of Formula I that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: June 4, 2010Publication date: January 27, 2011Inventors: Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
-
Publication number: 20110021420Abstract: The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.Type: ApplicationFiled: September 3, 2010Publication date: January 27, 2011Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Stephen Robert Bloom, Mohammad Ali Ghatei, Caroline Jane Small, Catherine Louise Dakin
-
Publication number: 20110003737Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: July 1, 2010Publication date: January 6, 2011Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. GUZZO, Matthew David SURMAN, Alan John HENDERSON, Mark HADDEN, Emily Elizabeth FREEMAN
-
Publication number: 20100323955Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.Type: ApplicationFiled: November 14, 2007Publication date: December 23, 2010Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Jonathan David Roth, Alain D. Baron, Christen Anderson
-
Publication number: 20100317572Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of Formula I and an anti-obesity compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating obesity or an obesity associated disease.Type: ApplicationFiled: December 18, 2008Publication date: December 16, 2010Applicant: NeuroSearch A/SInventor: Jens Damsgaard Mikkelsen
-
Publication number: 20100285145Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: May 6, 2010Publication date: November 11, 2010Inventors: Etzer Darout, Michael P. DeNinno, Kentaro Futatsugi, Cristiano Guimaraes, Bruce A. Lefker, Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson